Inari Medical: Return On Capital Employed Insights

Looking at Q1, Inari Medical NARI earned $7.71 million, a 10.25% increase from the preceding quarter. Inari Medical also posted a total of $57.40 million in sales, a 18.08% increase since Q4. Inari Medical earned $7.00 million, and sales totaled $48.61 million in Q4.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Inari Medical's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Inari Medical posted an ROCE of 0.04%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Inari Medical, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.

Q1 Earnings Recap

Inari Medical reported Q1 earnings per share at $0.13/share, which beat analyst predictions of $0.05/share.